Table 1.
Patient characteristics.
| Characteristics | Total N = 324 | MAVERICC | P-value | |
|---|---|---|---|---|
| FOLFOX + BEV (Oxaliplatin cohort) N = 161 | FOLFIRI + BEV (Irinotecan cohort) N = 163 | |||
| Sex | 0.93 | |||
| Male | 204 | 101 (62.7%) | 103 (63.2%) | |
| Female | 120 | 60 (37.3%) | 60 (36.8%) | |
| Age | 0.04 | |||
| ≤65 | 218 | 117 (72.7%) | 101 (62.0%) | |
| >65 | 106 | 44 (27.3%) | 62 (38.0%) | |
| Performance status | 0.11 | |||
| ECOG 0 | 178 | 81 (50.3%) | 97 (59.5%) | |
| ECOG 1 | 145 | 79 (49.1%) | 66 (40.5%) | |
| Unknown* | 1 | 1 (0.6%) | 0 (0%) | |
| Primary tumour site | 0.80 | |||
| Right-sided | 131 | 64 (39.8%) | 67 (41.1%) | |
| Left-sided | 193 | 97 (60.2%) | 96 (58.9%) | |
| Number of metastases | 0.67 | |||
| ≤2 | 207 | 101 (62.7%) | 106 (65.0%) | |
| >2 | 117 | 60 (37.3%) | 57 (35.0%) | |
| Primary tumour resected | 0.50 | |||
| No | 301 | 148 (91.9%) | 153 (93.9%) | |
| Yes | 23 | 13 (8.1%) | 10 (6.1%) | |
| Adjuvant chemotherapy | 0.39 | |||
| No | 289 | 146 (90.7%) | 143 (87.7%) | |
| Yes | 35 | 15 (9.3%) | 20 (12.3%) |
P-values was estimated by Chi-square test.
BEV bevacizumab, ECOG Eastern Cooperative Oncology Group.
*Unknown group was not included in the analysis.